Q2 2026 saw 2% U.S. RevPAR growth, 4% net room growth, and $212M adjusted EBITDA, with strong pipeline expansion and industry-leading margins. Outlook for 2026 is positive, with raised RevPAR guidance and robust capital allocation.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.